Ultraviolet related DNA-damage in skin of patients with atopic dermatitis and atopic status in relation to the use of Myfortic®

Ultraviolet related DNA-damage in skin of patients with atopic dermatitis and atopic status in relation to the use of Myfortic® - Effect of Myfortic® on UV-induced DNA-damage and atopic status

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30341

Enrollment

Registered

2006-10-17

Start date

2007-03-13

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis atopic eczema

Interventions

As mentioned in study design.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age from 18 years - atopic dermatitis according to the criteria of Hanifin and Rajka - insufficient respons to topical therapy alone - the physician estimates that treatment with oral immunosuppressiva agents is indicated.

Exclusion criteria

Exclusion criteria: - patients with any known hypersensitivity to mycofenolic acid or other components of the formulation. - oral immunosuppressive treatment in the last 6 weeks. - concomittant UV therapy or UV therapy in the last two months. - contact with UV on the laesional skin for the last two months. - patients with thrombocytopenia (

Design outcomes

Primary

Measure	Time frame
The difference between the percentage in repair of cyclobutane pyrimidine dimers (CPD's) before and after treatment with Myfortic is the primary study outcome.	—

Secondary

Measure	Time frame
The secundary study outcome is the atopic state before, during and after treatment with Myfortic	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)